Brief: TOT Biopharm International Says New Drug Application For Clinical Trial Of Tab014 Authorized By FDA
02/02/2021 01:29
Feb 2 (Reuters) - TOT BIOPHARM International Co Ltd
1875.HK :
* INVESTIGATIONAL NEW DRUG APPLICATION FOR PHASE III
CLINICAL
TRIAL OF TAB014 INTRAVITREAL INJECTION AUTHORIZED BY U.S. FDA
Source text for Eikon: ID:
Further company coverage: 1875.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioDlink International
See all newsCorrected: China's BioDlink International HY revenue falls (September 29)
Brief: Biodlink International To Deliver Ten Batches Of Monoclonal Antibody Intermediates To Wuxi Biologics
Brief: Biodlink International Says Shan Fu Resigns As Executive Director And Chairperson
Brief: BioDlink International Says WuXi XDC Cayman To Make Conditional Cash Offer For All Co Shares
Brief: HKEX Says Trading In Shares Of Biodlink International Will Be Halted At Dec 29